Skip to main content

Table 1 Demographic and clinical characteristics of study patients after matching

From: Low-dose intravenous plus inhaled versus intravenous polymyxin B for the treatment of extensive drug-resistant Gram-negative ventilator-associated pneumonia in the critical illnesses: a multi-center matched case–control study

  Total (n = 132) IH + IV polymyxin B (n = 44) IV polymyxin B (n = 88) p value
Age, mean years ± SD 65 ± 17 67 ± 17 64 ± 17 0.317
Sex, n (%) 103(78.0) 34(77.3) 69(78.4) 0.882
Etiology, n (%)
 Acute respiratory failure 54(40.9) 13(29.5) 41(46.6) 0.060
 Multiple trauma 27(20.5) 15(34.1) 12(13.6) 0.006
 Postoperative 31(23.5) 6(13.6) 25(28.4) 0.059
 Acute pancreatitis 12(9.1) 7 (15.9) 6(6.8) 0.108
 Others 9 (6.8) 4(9.1) 5(5.7) 0.714
Cause of ICU admission, n (%)
 Medical 73(55.3) 23(52.3) 50(56.8) 0.620
 Surgical 59(44.7) 21(47.7) 38(43.2)  
Comorbidities, n (%)
 Cardiovascular disease 50(37.9) 19(43.2) 31(35.2) 0.374
 Cerebrovascular disease 34(25.8) 7(15.9) 27(30.7) 0.067
 Chronic pulmonary disease 15(11.4) 5(11.4) 10(11.4)  > 0.999
 Chronic liver disease 5(3.8) 1(2.3) 4(4.5) 0.519
 Diabetes mellitus 21(15.9) 9(20.5) 12(13.6) 0.313
 Chronic kidney disease 20(15.2) 5(11.4) 15(17.0) 0.391
 Solid tumor 11(8.3) 5(11.4) 6(6.8) 0.373
 Hematological malignancies 7(5.3) 4(9.1) 3(3.4) 0.170
 Neutropenia 4(3.0) 2(4.5) 2(2.3) 0.473
 HIV 1(0.8) 0(0) 1(1.1) 0.478
 Charlson comorbidity index 2 ± 2 2 ± 1 2 ± 2 0.266
 Immunosuppressive status, n (%) 20(15.2) 9(20.5) 11(12.5) 0.230
Responsible pathogens, n (%)
 XDR Escherichia coli 4(3.0) 0(0.0) 4(4.5) 0.369
 XDR Klebsiella pneumoniae 63(47.7) 31(70.5) 32(36.4)  < 0.001
 XDR Acinetobacter baumannii 53 (40.2) 9(20.5) 44 (50.0) 0.001
 XDR Pseudomonas aeruginosa 12(9.1) 4(9.1) 8(9.1)  > 0.999
 Combination of other antibiotics 76(57.6) 24(54.5) 52(59.1) 0.618
Severity of disease
 SOFA score, mean scores ± SD 8 ± 4 9 ± 4 8 ± 4 0.308
 APACHE II score, mean scores ± SD 19 ± 6 18 ± 7 20 ± 5 0.265
 Bacteremia, n (%) 26(19.7) 8(18.2) 18(20.5) 0.757
 Sepsis or septic shock, n (%) 74(56.1) 24(54.5) 50(56.8) 0.764
 Single maintenance dose of Intravenous polymyxin B, mg/kg, median (IQR) 1.0(1.0, 1.5) 1.0(1.0, 1.25) 1.0(1.0, 1.5) 0.563
 Frequency of intravenous polymyxin B, median (IQR) 2.0(2.0,2.0) 2.0(2.0,2.0) 2.0(2.0,2.0)
 Loading dose of intravenous polymyxin B, mg/kg, median (IQR) 2.0(1.7,2.1) 2.0(1.8,2.1) 2.0(1.7,2.0) 0.652
 Dose of inhaled polymyxin B, mg/kg, median (IQR) 1.82(1.04,2.0)  
 Duration of polymyxin B therapy, mean days ± SD 11 ± 8 10 ± 7 12 ± 9 0.090
 History of antibiotics within 7 days, n (%) 113(85.6) 38(86.4) 75(85.2) 0.861
 History of glucocorticoid within 7 days, n (%) 41(31.1) 16(36.4) 25(28.4) 0.352
 Length of hospitalization, median (IQR) 33(20, 55) 35(23, 55) 33(18, 54) 0.647
 Length of ICU stay, median (IQR) 27(16, 41) 25(16, 37) 29(15, 47) 0.808
 Duration of mechanical ventilation, median (IQR) 18(11, 30) 18(9, 28) 18(11, 32) 0.827